Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-06 in previously untreated advanced non-squamous non-small cell lung cancer
PACTR202301834998443Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiragolumab, atezolizumab, pembrolizumab, pemetrexed, carboplatin and 1 more in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Roche. Primary endpoints: Investigator-assessed confirmed objective response rate, Investigator-assessed progression-free survival and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on PACTR202301834998443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202301834998443.